Biotechnology News and Research RSS Feed - Biotechnology News and Research

Scientists develop potential treatment to prevent hypertrophic cardiomyopathy

Scientists develop potential treatment to prevent hypertrophic cardiomyopathy

More than 15 years ago, David Warshaw, Ph.D., and coworkers discovered the precise malfunction of a specific protein in the heart that leads to hypertrophic cardiomyopathy, a common culprit in cases of sudden death in young athletes. [More]
Positive pre-clinical study data of Lamellar Biomedical's Visco-ease published in Supportive Care Journal

Positive pre-clinical study data of Lamellar Biomedical's Visco-ease published in Supportive Care Journal

Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical devices and pharmaceuticals, based on Lamellasome™ technology, is pleased to announce the publication of a paper in the Supportive Care in Cancer Journal. [More]
Mitochondria essential for cellular ageing

Mitochondria essential for cellular ageing

An international team of scientists has for the first time shown that mitochondria, the batteries of the cells, are essential for ageing. [More]
Study finding could shed light on molecular mechanisms underlying Huntington's disease

Study finding could shed light on molecular mechanisms underlying Huntington's disease

Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder. [More]
New gene cut-and-paste methods help correct disease-causing mutation in animal model

New gene cut-and-paste methods help correct disease-causing mutation in animal model

For the first time, researchers have treated an animal model of a genetic disorder using a viral vector to deliver genome-editing components in which the disease- causing mutation has been corrected. [More]
Lupin Pharmaceuticals releases Metformin HCl ER Tablets

Lupin Pharmaceuticals releases Metformin HCl ER Tablets

Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc., has launched its Metformin HCl ER Tablets, 500 mg and 1000 mg to market a generic equivalent of Santarus Inc.'s Glumetza HCl ER Tablets, 500 mg and 1000 mg. [More]
New way to more efficiently deliver CRISPR/Cas9 therapeutic to mice with Tyrosinemia type I

New way to more efficiently deliver CRISPR/Cas9 therapeutic to mice with Tyrosinemia type I

University of Massachusetts Medical School researchers have found a way to more efficiently delivery a CRISPR/Cas9 therapeutic to adult mice with the metabolic disease Tyrosinemia type I that may also prove to be safer for use in humans. [More]
MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer. [More]
Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others. [More]
Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Leaders of several cancer centers designated by the National Cancer Institute have united to support human papillomavirus vaccination. Among them is Cheryl Willman, MD, Director and CEO of the University of New Mexico Comprehensive Cancer Center. [More]
Genes that influence people's health also have impact on some cognitive functions

Genes that influence people's health also have impact on some cognitive functions

Genes that influence people's health also shape how effectively they think, a study shows. Scientists found that genes associated with diseases including Alzheimer's disease, schizophrenia, and autism also have an impact on some cognitive functions. [More]
Halozyme closes $150 million royalty-backed debt transaction

Halozyme closes $150 million royalty-backed debt transaction

Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta. [More]
New humidity sensors could help combat proliferation of bacteria

New humidity sensors could help combat proliferation of bacteria

The Telecommunications Engineer Aitor Urrutia-Azcona has designed some humidity sensors with anti-bacterial properties that combat the proliferation of micro-organisms in environments where the humidity level is very high, such as hospitals and industrial premises for foodstuffs or pharmaceutical products. [More]
Biomedical innovation in the UK: an interview with Zahid Latif

Biomedical innovation in the UK: an interview with Zahid Latif

The biomedical research base is one of the UK's strengths; over 1500 companies in the Pharmaceuticals and biotechnology area are established in the UK employing over 70,000. [More]
Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan. [More]
Champions Oncology begins prospective correlative trial of PDX in patients with sarcoma

Champions Oncology begins prospective correlative trial of PDX in patients with sarcoma

Champions Oncology today announced that it has initiated a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft PDX models) in patients with metastatic or recurrent sarcoma. Mount Sinai Hospital in Toronto, Canada is the first clinical site to enroll patients in the newly-opened study. [More]
Oxeia accelerating development of neurometabolic treatments for concussions

Oxeia accelerating development of neurometabolic treatments for concussions

Oxeia Biopharmaceuticals, Inc., a biotechnology company, is catalyzing the development of first-in-class neurometabolic treatments for concussions and other aspects of brain injury. [More]
AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology. [More]
Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach. [More]
CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

Colorado State University's Biopharmaceutical Manufacturing and Academic Resource Center has been awarded a 10-month, $4.6 million contract funded by the Department of Defense to help develop and manufacture new vaccines to fight encephalitic viruses that cause inflammation of the brain. [More]
Advertisement
Advertisement